Target-mediated drug disposition and dynamics

Biochemical Pharmacology

Volumn 72, Issue 1, 2006, Pages 1-10

  Mager, Donald E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Mathematical modeling; Nonlinear pharmacokinetics; Pharmacodynamics; Target mediated drug disposition

Indexed keywords

ABCIXIMAB; BETA1 INTERFERON; BUSULFAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EFALIZUMAB; FLUOROURACIL; GAMMA INTERFERON; IMIRESTAT; LEUKEMIA INHIBITORY FACTOR; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD 11; NATALIZUMAB; NEOPTERIN; NORSELEGILINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SELEGILINE; THROMBOPOIETIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VASCULOTROPIN; WARFARIN;

ARTICLE; COMPARTMENT MODEL; COMPUTER SIMULATION; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISPOSITION; DRUG ELIMINATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG UPTAKE; ENDOCYTOSIS; ERYTHROID PRECURSOR CELL; FIRST PASS EFFECT; HUMAN; MATHEMATICAL MODEL; MEAN ARTERIAL PRESSURE; MICHAELIS MENTEN KINETICS; MULTIPLE SCLEROSIS; NEGATIVE FEEDBACK; NEUTROPENIA; NEUTROPHILIA; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; RECEPTOR OCCUPANCY; RECEPTOR UPREGULATION; STOICHIOMETRY;

EID: 33646901012     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.12.041     Document Type: Note

References (72)

1. Lin J.H. Dose-dependent pharmacokinetics: experimental observations and theoretical considerations. Biopharm Drug Dispos 15 (1994) 1-31
2. Ludden T.M. Nonlinear pharmacokinetics: clinical implications. Clin Pharmacokinet 20 (1991) 429-446
3. Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 56 (1994) 248-252
4. Tang L., Persky A.M., Hochhaus G., and Meibohm B. Pharmacokinetic aspects of biotechnology products. J Pharm Sci 93 (2004) 2184-2204
5. Lobo E.D., Hansen R.J., and Balthasar J.P. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93 (2004) 2645-2668
6. Abdel-Rahman S.M., and Kauffman R.E. The integration of pharmacokinetics and pharmacodynamics: understanding dose-response. Annu Rev Pharmacol Toxicol 44 (2004) 111-136
7. Till A.E., Gomez H.J., Hichens M., Bolognese J.A., McNabb W.R., Brooks B.A., et al. Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers. Biopharm Drug Dispos 5 (1984) 273-280
8. Brazzell R., Mayer P., Dobbs R., McNamara P., Teng R., and Slattery J. Dose-dependent pharmacokinetics of the aldose reductase inhibitor imirestat in man. Pharm Res 8 (1991) 112-118
9. Cheung W.K., and Levy G. Comparative pharmacokinetics of coumarin anticoagulants XLIX: nonlinear tissue distribution of S-warfarin in rats. J Pharm Sci 78 (1989) 541-546
10. Chien J.Y., Banfield C.R., Brazzell R.K., Mayer P.R., and Slattery J.T. Saturable tissue binding and imirestat pharmacokinetics in rats. Pharm Res 9 (1992) 469-473
11. Hazelett S.E., and Preusch P.C. Tissue distribution and warfarin sensitivity of Vitamin K epoxide reductase. Biochem Pharmacol 37 (1988) 929-934
12. Thijssen H.H., and Baars L.G. Microsomal warfarin binding and Vitamin K 2,3-epoxide reductase. Biochem Pharmacol 38 (1989) 1115-1120
13. Lees K.R., Kelman A.W., Reid J.L., and Whiting B. Pharmacokinetics of an ACE inhibitor, S-9780, in man: evidence of tissue binding. J Pharmacokinet Biopharm 17 (1989) 529-550
14. Weber C., Schmitt R., Birnboeck H., Hopfgartner G., van Marle S., Peeters P., et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 60 (1996) 124-137
15. Laine K., Anttila M., Huupponen R., Maki-Ikola O., and Heinonen E. Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding. Clin Neuropharmacol 23 (2000) 22-27
16. Mahmood I., and Green M.D. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin Pharmacokinet 44 (2005) 331-347
17. Terashi K., Oka M., Ohdo S., Furukubo T., Ikeda C., Fukuda M., et al. Close association between clearance of recombinant human granulocyte colony-stimulating factor (G-CSF) and G-CSF receptor on neutrophils in cancer patients. Antimicrob Agents Chemother 43 (1999) 21-24
18. Mufson R.A., and Gesner T.G. Binding and internalization of recombinant human erythropoietin in murine erythroid precursor cells. Blood 69 (1987) 1485-1490
19. Chapel S., Veng-Pedersen P., Hohl R.J., Schmidt R.L., McGuire E.M., and Widness J.A. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther 298 (2001) 820-824
20. Meijer R.T., Koopmans R.P., ten Berge I.J., and Schellekens P.T. Pharmacokinetics of murine anti-human CD3 antibodies in man are determined by the disappearance of target antigen. J Pharmacol Exp Ther 300 (2002) 346-353
21. Jusko W.J. Guidelines for collection and analysis of pharmacokinetic data. In: Evans W.E., Schentag J.J., and Jusko WJ. (Eds). Applied pharmacokinetics (1992), Applied Therapeutics Inc., Vancouver (Chapter 2)
22. Caprani O., Sveinsdottir E., and Lassen N. SHAM, a method for biexponential curve resolution using initial slope, height, area and moment of the experimental decay type curve. J Theor Biol 52 (1975) 299-315
23. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 4 (2005) 510-518
24. Sheremata W.A., Vollmer T.L., Stone L.A., Willmer-Hulme A.J., and Koller M. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology 52 (1999) 1072-1074
25. Foster D.M. Noncompartmental vs. compartmental approaches to pharmacokinetic analysis. In: Atkinson A.J., Daniels C.E., Dedrick R.L., Grudzinskas C.V., and Markey S.P. (Eds). Principles of clinical pharmacology (2001), Academic Press, New York 75-92
26. Bellissant E., Sebille V., and Paintaud G. Methodological issues in pharmacokinetic-pharmacodynamic modelling. Clin Pharmacokinet 35 (1998) 151-166
27. Michaelis L., and Menten M.L. Die Kinetik der Invertinwirkung. Biochem Z 49 (1913) 333-369
28. Jusko W.J. Pharmacokinetics of capacity-limited systems. J Clin Pharmacol 29 (1989) 488-493
29. McNamara P.J., Slattery J.T., Gibaldi M., and Levy G. Accumulation kinetics of drugs with nonlinear plasma protein and tissue binding characteristics. J Pharmacokinet Biopharm 7 (1979) 397-405
30. Oie S., Guentert T.W., and Tozer T.N. Effect of saturable binding on the pharmacokinetics of drugs: a simulation. J Pharm Pharmacol 32 (1980) 471-477
31. Wagner J.G. A new generalized nonlinear pharmacokinetic model and its implications. In: Wagner J.G. (Ed). Biopharmaceutics and relevant pharmacokinetics (1971), Drug Intelligence Publications, Hamilton, IL 302-317
32. Snoeck E., Jacqmin P., Peer A., and Danhof M. A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine. J Pharmacokinet Biopharm 27 (1999) 257-280
33. Bischoff K.B., Dedrick R.L., Zaharko D.S., and Longstreth J.A. Methotrexate pharmacokinetics. J Pharm Sci 60 (1971) 1128-1133
34. Levy G., Mager D.E., Cheung W.K., and Jusko W.J. Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man. J Pharm Sci 92 (2003) 985-994
35. Coffey G.P., Fox J.A., Pippig S., Palmieri S., Reitz B., Gonzales M., et al. Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice. Drug Metab Dispos 33 (2005) 623-629
36. Bauer R.J., Dedrick R.L., White M.L., Murray M.J., and Garovoy M.R. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 27 (1999) 397-420
37. Ng C.M., Joshi A., Dedrick R.L., Garovoy M.R., and Bauer R.J. Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm Res 22 (2005) 1088-1100
38. Gianni L., Kearns C.M., Giani A., Capri G., Vigano L., Lacatelli A., et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13 (1995) 180-190
39. Mager D.E., and Jusko W.J. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28 (2001) 507-532
40. Sugiyama Y., and Hanano M. Receptor-mediated transport of peptide hormones and its importance in the overall hormone disposition in the body. Pharm Res 6 (1989) 192-202
41. Wiley H.S., and Cunningham D.D. A steady state model for analyzing the cellular binding, internalization and degradation of polypeptide ligands. Cell 25 (1981) 433-440
42. Rippley R.K., and Stokes C.L. Effects of cellular pharmacology on drug distribution in tissues. Biophys J 69 (1995) 825-839
43. King S.Y., Joslin M.A., Raudibaugh K., Pieniaszek Jr. H.J., and Benedek I.H. Dose-dependent pharmacokinetics of warfarin in healthy volunteers. Pharm Res 12 (1995) 1874-1877
44. Eppler S.M., Combs D.L., Henry T.D., Lopez J.J., Ellis S.G., Yi J.H., et al. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther 72 (2002) 20-32
45. Jin F., and Krzyzanski W. Pharmacokinetic model of target-mediated disposition of thrombopoietin. AAPS Pharm Sci 6 (2004) E9
46. Segrave A.M., Mager D.E., Charman S.A., Edwards G.A., and Porter C.J. Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep. J Pharmacol Exp Ther 309 (2004) 1085-1092
47. Porter C.J.H., and Charman S.A. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci 89 (2000) 297-310
48. Radwanski E., Chakraborty A., Van Wart S., Huhn R.D., Cutler D.L., Affrime M.B., et al. Pharmacokinetics and leukocyte responses of recombinant human interleukin-10. Pharm Res 15 (1998) 1895-1901
49. Kemme M.J., Schoemaker R.C., Burggraaf J., van der Linden M., Noordzij M., Moerland M., et al. Endothelial binding of recombinant tissue plasminogen activator: quantification in vivo using a recirculatory model. J Pharmacokinet Pharmacodyn 30 (2003) 3-22
50. Mager D.E., and Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 22 (2005) 1589-1596
51. Thijssen H., and Janssen Y. Target-based warfarin pharmacokinetics in the rat: the link with the anticoagulant effect. J Pharmacol Exp Ther 270 (1994) 554-558
52. Levy G. Mechanism-based pharmacodynamic modeling. Clin Pharmacol Ther 56 (1994) 356-358
53. Mager D.E., Wyska E., and Jusko W.J. Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 31 (2003) 510-518
54. Toutain P.L., Lefebvre H.P., and King J.N. Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach. J Pharmacol Exp Ther 292 (2000) 1087-1093
55. Mager D.E., Mascelli M.A., Kleiman N.S., Fitzgerald D.J., and Abernethy D.R. Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. J Pharmacol Exp Ther 307 (2003) 969-976
56. Kereiakes D.J., Broderick T.M., Roth E.M., Whang D., Mueller M., Lacock P., et al. High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists. J Thromb Thrombolysis 9 (2000) 149-155
57. Kang W., and Weiss M. Digoxin uptake, receptor heterogeneity, and inotropic response in the isolated rat heart: a comprehensive kinetic model. J Pharmacol Exp Ther 302 (2002) 577-583
58. Mager D.E., Neuteboom B., Efthymiopoulos C., Munafo A., and Jusko W.J. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta 1a in monkeys. J Pharmacol Exp Ther 306 (2003) 262-270
59. Mager D.E., and Jusko W.J. Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-beta 1a in humans. Pharm Res 19 (2002) 1537-1543
60. Sharma A., Ebling W.F., and Jusko W.J. Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J Pharm Sci 87 (1998) 1577-1584
61. Jonsson E.N., Macintyre F., James I., Krams M., and Marshall S. Bridging the pharmacokinetics and pharmacodynamics of UK-279,276 across healthy volunteers and stroke patients using a mechanistically based model for target-mediated disposition. Pharm Res 22 (2005) 1236-1246
62. Rudin M., and Weissleder R. Molecular imaging in drug discovery and development. Nat Rev Drug Discov 2 (2003) 123-131
63. Smith-Jones P.M., Solit D.B., Akhurst T., Afroze F., Rosen N., and Larson S.M. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 22 (2004) 701-706
64. Gunn R.N., Gunn S.R., Turkheimer F.E., Aston J.A., and Cunningham V.J. Positron emission tomography compartmental models: a basis pursuit strategy for kinetic modeling. J Cereb Blood Flow Metab 22 (2002) 1425-1439
65. Millet P., Ibanez V., Delforge J., Pappata S., and Guimon J. Wavelet analysis of dynamic PET data: application to the parametric imaging of benzodiazepine receptor concentration. Neuroimage 11 (2000) 458-472
66. Lappin G., and Garner R.C. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov 2 (2003) 233-240
67. Mehvar R. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. J Pharm Pharmaceut Sci 3 (2000) 125-136
68. Sarkar C.A., Lowenhaupt K., Horan T., Boone T.C., Tidor B., and Lauffenburger D.A. Rational cytokine design for increased lifetime and enhanced potency using pH-activated "histidine switching". Nat Biotechnol 20 (2002) 908-913
69. Mager D.E., Neuteboom B., and Jusko W.J. Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys. Pharm Res 22 (2005) 58-61
70. McKenna S.D., Vergilis K., Arulanandam A.R., Weiser W.Y., Nabioullin R., and Tepper M.A. Formation of human IFN-beta complex with the soluble type I interferon receptor IFNAR-2 leads to enhanced IFN stability, pharmacokinetics, and antitumor activity in xenografted SCID mice. J Interferon Cytokine Res 24 (2004) 119-129
71. Qian Z.M., Li H., Sun H., and Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 54 (2002) 561-587
72. Hilgenbrink A.R., and Low P.S. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci 94 (2005) 2135-2146